Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis.

Experimental hematology - 1 Sept 2016

Daitoku Shinya, Takenaka Katsuto, Yamauchi Takuji, Yurino Ayano, Jinnouchi Fumiaki, Nunomura Takuya, Eto Tetsuya, Kamimura Tomohiko, Higuchi Masakazu, Harada Naoki, Saito Noriyuki, Miyamoto Toshihiro, Iwasaki Hiromi, Akashi Koichi

Abstract excerpt

Somatic mutations of calreticulin (CALR) have been observed in many cases of essential thrombocythemia (ET) or primary myelofibrosis that harbor non-mutated Janus kinase 2 (JAK2). CALR mainly localizes within the endoplasmic reticulum lumen, but a small fraction of the total CALR pool is distributed over the cell surface. Cell surface CALR is known to transduce prophagocytic "eat me" signals to macrophages and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to Hematopoietic Stem Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunophenotyping

Share to Janus Kinase 2

Share to Phagocytosis

Share to Polycythemia Vera

Share to Receptors, Thrombopoietin

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 27185380
DOI: 10.1016/j.exphem.2016.05.001

Genes

CALR
JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis.PMID 27185380Read ↗

Mutant Calreticulin in the Myeloproliferative NeoplasmsSemantic proximity Read ↗

Calreticulin mutations in myeloproliferative neoplasms.Semantic proximity Read ↗

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.Semantic proximity Read ↗

The role of calreticulin mutations in myeloproliferative neoplasms.Semantic proximity Read ↗

Frequency of Calreticulin (CALR) Mutation and Its Clinical Prognostic Significance in Essential Thrombocythemia and Primary Myelofibrosis: A Meta-analysis.Semantic proximity Read ↗

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value.Semantic proximity Read ↗

Somatic mutations of calreticulin in myeloproliferative neoplasms.Semantic proximity Read ↗

Calreticulin Mutations in Myeloproliferative NeoplasmsSemantic proximity Read ↗

Effects of calreticulin mutations on cell transformation and immunity.Semantic proximity Read ↗

Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.Semantic proximity Read ↗

Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study.Semantic proximity Read ↗

Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.